

- 241548809_eng.pdf?sequence=1&isAllowed=y
13. U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases. Division of AIDS table for grading the severity of adult and pediatric adverse events. Corrected Version 2.1. Available from: <https://rsc.niaid.nih.gov/clinical-research-sites/table-grading-severity-adult-pediatric-adverse-events-changes-highlighted>
 14. R Core Team. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2018.
 15. Hewison C, Bastard M, Khachatryan N, et al. Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia. *Int J Tuberc Lung Dis* 2018;22:766-72.
 16. Mbuagbaw L, Guglielmetti L, Hewison C, et al. Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis. *Emerg Infect Dis* 2019;25:936-43.
 17. Lorent N, Sebatunzi O, Mukeshimana G, et al. Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: A prospective cohort study. *PLoS One* 2011;6:e19566.
 18. Van der Walt M, Lancaster J, Odendaal R, et al. Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients. *PLoS One* 2013;8:e58817.
 19. Schnippel K, Firmhaber C, Berhanu R, et al. Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. *J Antimicrob Chemother* 2017;72:1871-9.
 20. Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. *Eur Respir J* 2017;49:1700387.
 21. Kalandarova L, Tillashaikhov M, Parpieva N, et al. Treatment outcomes and adverse reactions in patients with multidrug-resistant tuberculosis managed by ambulatory or hospitalized care from 2010-2011 in Tashkent, Uzbekistan. *Public Heal Panor* 2016;02:21-9.
 22. WHO. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. Available from: <https://apps.who.int/iris/handle/10665/332397>
 23. Hwang TJ, Wares DF, Jafarov A, et al. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. *Int J Tuberc Lung Dis* 2013;17:1257-66.
 24. Walker IF, Khanal S, Hicks JP, et al. Implementation of a psychosocial support package for people receiving treatment for multidrug-resistant tuberculosis in Nepal: A feasibility and acceptability study. *PLoS One* 2018;13:e0201163.
 25. Huque R, Elsey P, Bieroze F, et al. "Death is a better option than being treated like this": a prevalence survey and qualitative study of depression among multi-drug resistant tuberculosis in-patients. *BMC Public Health* 2020;20:848.

Creative Commons Attribution 3.0 licence